TW202317514A - 新穎方法 - Google Patents

新穎方法 Download PDF

Info

Publication number
TW202317514A
TW202317514A TW111123528A TW111123528A TW202317514A TW 202317514 A TW202317514 A TW 202317514A TW 111123528 A TW111123528 A TW 111123528A TW 111123528 A TW111123528 A TW 111123528A TW 202317514 A TW202317514 A TW 202317514A
Authority
TW
Taiwan
Prior art keywords
piperidine
typically
solvent
group
protected
Prior art date
Application number
TW111123528A
Other languages
English (en)
Chinese (zh)
Inventor
保羅 弗瑞瑟
捷達 帕爾古納
瑪萊許 巴拉沙
喬瑟芬 E F 辛誇爾
瑞吉斯 J G 蒙迪爾
派洛 托莎蒂
Original Assignee
瑞士商F 霍夫曼拉羅氏股份公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商F 霍夫曼拉羅氏股份公司 filed Critical 瑞士商F 霍夫曼拉羅氏股份公司
Publication of TW202317514A publication Critical patent/TW202317514A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/04—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from amines with formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/56—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/98—Nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW111123528A 2021-06-23 2022-06-23 新穎方法 TW202317514A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202141028180 2021-06-23
IN202141028180 2021-06-23

Publications (1)

Publication Number Publication Date
TW202317514A true TW202317514A (zh) 2023-05-01

Family

ID=82458485

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111123528A TW202317514A (zh) 2021-06-23 2022-06-23 新穎方法

Country Status (12)

Country Link
US (1) US20240150291A1 (cg-RX-API-DMAC7.html)
EP (1) EP4359385A2 (cg-RX-API-DMAC7.html)
JP (1) JP2024524215A (cg-RX-API-DMAC7.html)
KR (1) KR20240024842A (cg-RX-API-DMAC7.html)
CN (1) CN118019727A (cg-RX-API-DMAC7.html)
AR (1) AR126215A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022300325A1 (cg-RX-API-DMAC7.html)
CA (1) CA3219597A1 (cg-RX-API-DMAC7.html)
IL (1) IL308071A (cg-RX-API-DMAC7.html)
MX (1) MX2023014547A (cg-RX-API-DMAC7.html)
TW (1) TW202317514A (cg-RX-API-DMAC7.html)
WO (1) WO2022268935A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI876271B (zh) * 2022-02-15 2025-03-11 瑞士商赫孚孟拉羅股份公司 新穎方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4638422A1 (en) * 2022-12-23 2025-10-29 F. Hoffmann-La Roche AG Proccesses for the preparation of an nlrp3 inhibitor
WO2025036914A1 (en) 2023-08-16 2025-02-20 F. Hoffmann-La Roche Ag Process for the preparation of preparing 1-ethyl-n-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)piperidine-4-sulfonamide
TW202545527A (zh) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Nlrp3及glp-1a組合療法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA917435B (en) * 1990-09-26 1992-05-27 Takeda Chemical Industries Ltd Herbicides
CA2059450A1 (en) * 1991-01-24 1992-07-25 Nobuyuki Sakashita Subsituted pyridinesulfonamide compound or its salt, process for preparing the same, and herbicide containing the same
EP0981526B1 (en) * 1997-05-02 2004-02-25 Dr. Reddy's Laboratories Ltd. Novel antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
DK1340757T3 (da) * 2000-11-16 2007-02-12 Sankyo Co 1-methylcarbapenemderivater
EP1403255A4 (en) * 2001-06-12 2005-04-06 Sumitomo Pharma RHO KINASE INHIBITORS
CN100360130C (zh) * 2002-04-18 2008-01-09 先灵公司 用作组胺h3拮抗剂的1-(4-哌啶基)苯并咪唑酮
EP1677783A2 (en) * 2003-10-08 2006-07-12 Nicholas Piramal India Limited Fibrinogen receptor antagonists and their use
DOP2006000009A (es) * 2005-01-13 2006-08-15 Arena Pharm Inc Procedimiento para preparar eteres de pirazolo [3,4-d] pirimidina
ZA200904857B (en) * 2007-02-22 2010-09-29 Merck Serono Sa Quinoxaline compounds and use thereof
US20120196889A1 (en) * 2009-02-25 2012-08-02 H. Lundbeck A/S Catecholamine derivatives and prodrugs thereof
JP5898962B2 (ja) * 2012-01-11 2016-04-06 東京応化工業株式会社 レジスト組成物及びレジストパターン形成方法
WO2017095758A1 (en) * 2015-12-01 2017-06-08 Merck Sharp & Dohme Corp. Homobispiperidinyl derivatives as liver x receptor beta agonists, compositions, and their use
CN110914256A (zh) * 2017-07-07 2020-03-24 英夫拉索姆有限公司 新颖磺酰胺羧酰胺化合物
GB201712282D0 (en) * 2017-07-31 2017-09-13 Nodthera Ltd Selective inhibitors of NLRP3 inflammasome
TW201910314A (zh) * 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
CN111902141A (zh) * 2018-03-26 2020-11-06 C4医药公司 用于ikaros降解的羟脑苷脂结合剂
CR20200588A (es) * 2018-05-04 2021-06-24 Inflazome Ltd Compuestos novedosos
CR20210148A (es) * 2018-09-21 2021-05-18 Novartis Ag Compuestos de isoxazol carboxamida y usos de los mismos
GB201817038D0 (en) 2018-10-19 2018-12-05 Inflazome Ltd Novel processes
GB201819083D0 (en) * 2018-11-23 2019-01-09 Inflazome Ltd Novel compounds
WO2020157069A1 (en) * 2019-01-28 2020-08-06 NodThera Limited Amino heterocyclic compounds and uses thereof
CN111393415B (zh) * 2020-04-30 2020-11-20 苏州信诺维医药科技有限公司 一种杂芳腈类化合物及其应用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI876271B (zh) * 2022-02-15 2025-03-11 瑞士商赫孚孟拉羅股份公司 新穎方法

Also Published As

Publication number Publication date
EP4359385A2 (en) 2024-05-01
US20240150291A1 (en) 2024-05-09
IL308071A (en) 2023-12-01
WO2022268935A2 (en) 2022-12-29
CN118019727A (zh) 2024-05-10
KR20240024842A (ko) 2024-02-26
MX2023014547A (es) 2024-04-29
AU2022300325A8 (en) 2023-11-16
JP2024524215A (ja) 2024-07-05
AU2022300325A1 (en) 2023-11-02
CA3219597A1 (en) 2022-12-29
WO2022268935A3 (en) 2023-02-02
AR126215A1 (es) 2023-09-27

Similar Documents

Publication Publication Date Title
AU2021212669B2 (en) GLP-1R modulating compounds
JP2025527298A (ja) 三環式化合物及びその医薬用途
TWI658042B (zh) 雜環化合物的合成
KR20240024842A (ko) Nlrp3 억제제의 제조 공정
TW202547822A (zh) 4-纈胺醯氧基丁酸的合成方法
KR20200057705A (ko) 리보시클립 및 그의 염의 제조를 위한 개선된 방법
JP2018521005A (ja) ウレア誘導体、またはその薬理学的に許容される塩
JP2024123202A (ja) 大環状化合物とその使用
WO2022214645A1 (en) Processes and intermediates for the preparation of relugolix
CN106220624A (zh) 阿哌沙班合成中的关键中间体和杂质:阿哌沙班二醇酯
KR102477924B1 (ko) 인돌 카르복스아미드 화합물을 제조하는 방법
TW202448866A (zh) 治療性化合物
US20240400516A1 (en) Processes for the preparation of 1,2,3,5,6,7-hexahydro-s-indacene derivataives
HK1225388A1 (zh) 通过环化2-(氨基乙氧基)苯甲酸衍生物制备3,4-二氢-1,4-苯并氧氮杂环庚三烯-5(2h)-酮衍生物
WO2022094668A1 (en) Process for preparing heterocyclic methanone compounds and aza-bicyclo intermediates thereof
CA2648369A1 (en) Polymorphic forms of (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4?l)-1-oxo-2,6-dihydro-1h-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide
CN109748927A (zh) 杂芳基酰胺类化合物、其制备方法、药用组合物及其应用
HK40105889A (en) Process for the preparation of nlrp3 inhibitors
JP2026502847A (ja) Nlrp3阻害剤の調製のためのプロセス
JP2016172755A (ja) 抗ウイルス化合物およびその有用な中間体の調製方法
HK40116804A (en) Glp-1r modulating compounds
CN118234729A (zh) 用于制备双环甘氨酸-脯氨酸化合物和其单环甘氨酸-脯氨酸中间体的方法
HK40085187A (en) Glp-1r modulating compounds
HK40085187B (en) Glp-1r modulating compounds